Solodyn News
Medicis' fourth-quarter revenue soars 42 percent - East Valley Tribune
And the company is working just as diligently to protect its patent for star acne product Solodyn, which has been challenged by a possible generic, ...
Medicis' 4th-quarter revenue soars 42%: Scottsdale drug firm ... - Trading Markets (press release)
And the company is working just as diligently to protect its patent for star acne product Solodyn, which has been challenged by a possible generic, ...
Medicis Shares Jump on 4Q Profit Surge - CNNMoney.com
... a $32 price target, citing increasing competition for dermal fillers _ used to treat wrinkles _ and generic competition for the acne treatment Solodyn. ...
Medicis 4Q sales up 42% to $140.3M vs TF avg est $130M - CNNMoney.com
The company attributed robust sales to prescriptions of its core acne products: Solodyn, Triaz and Ziana. Medicis provided first-quarter guidance for ...
Medicis' fourth-quarter revenue soars 42 percent - East Valley Tribune
And the company is working just as diligently to protect its patent for star acne product Solodyn, which has been challenged by a possible generic, ...
Medicis 4Q Profit Rises on Acne Products - Forbes
Sales of acne treatments, which include Solodyn, Triaz and Ziana, rose 22 percent to $79.5 million, while non-acne products sales rose 80 percent to $46.9 ...
S&P Equity Research Downgrades Medicis Pharmaceutical (MRX) to ... - StreetInsider.com (subscription)
We are also concerned about generic challenges to MRX's key Solodyn acne drug, as well as by the effects of a weakening economy on discretionary items such ...
Tuesday's Options Report: Citi, XLF, HBC, MRX, SGP, Apple, EMC - Seeking Alpha
... 10% of their value in am trading, after Impax Laboratories sought FDA approval for a generic version of Medicis’ best-selling anti-acne drug, Solodyn. ...
Medicis Key Drug Faces Patent Challenge - CNNMoney.com
Impax is seeking approval to sell a generic version of Solodyn. Hayward, Calif.-based Impax didn't tell Medicis about the timing or status of the FDA's ...
Medicis Says IMPAX Files For Generic Version Of Solodyn - Quick Facts - Trading Markets (press release)
In its letter, IMPAX makes no mention of Medicis' numerous pending patent applications, and refers only to Medicis' issued patent covering Solodyn, ...
Solodyn RSS Feed